eral such trials provide the strongest evidence concerning a specifi c treatment. Among other features, clinical interventional trials are characterized by a prospective defi nition of primary and secondary objectives. In some clinical interventional trials prognostic or quality of life studies are integrated as secondary objectives [ 19 ] . Furthermore, they ensure high patient safety by structured reporting of adverse events including serious adverse events, data safety monitoring and stopping rules. The randomization may allow scientifi c evaluation of the scientifi c hypothesis irrespective of a population based patient recruitment and independent of patient selection. However, in rare entities, the study cohort may be too small for statistically meaningful randomized comparison, even in a global setting. Moreover, in a heterogeneous entity such as pediatric soft tissue sarcoma or even acute lymphoblastic leukemia, only a sub-cohort may be eligible for such a randomized comparison [ 1 , 3 , 18 ] . In some instances, consecutive generations of therapy optimization trials are compared to each other, and changes in therapeutic management are compared [ 26 ] . However, these historical comparisons provide weaker evidence compared to randomized comparison, mainly because of a inherent bias associated with medical trends over time, e. g. better management of therapy-associated complications. There are several options to ensure that patients ineligible for RCTs may not be lost to prospective registration and a structured generation of good evidence. Here, diagnostic studies and registries may play an important role. Both focus on diff erent aspects. In fact, diagnostic studies constitute the stronger tool for generating evidence than pure clinical registries. Diagnostic studies evaluate the impact of a specifi c diagnostic test in a therapeutic setting that basically represents the current standard treatment recommendation. According to the concept of Sackett and Haynes [ 22 ] , phase I diagnostic studies may help to distinguish between patients with a specifi c disease and normal individuals. Phase II studies evaluate whether a specifi c test result is more likely associated with a target disorder than other test results, while phase III questions focus on the diagnostic accuracy of a specifi c test in patients, in whom it is clinically reasonable to suspect a specifi c diagnosis. Thus, phase III studies are strongest in testing the diagnostic usefulness for clinical application [ 2 ] . Last, the prognostic impact of a diagnostic test is evaluated in phase IV diagnostic studies [ 21 ] . Ideally, it should also be shown whether patients may benefi t from a Evidence-based medicine is one of the most prominent keywords in modern medicine. According to the concepts of evidence-based medicine, diff erent levels of evidence are defi ned. These may range from expert opinion or single case reports to clinical studies, prospective randomized trials and ultimately the meta-analysis of several prospective randomized controlled trials (RCT). In interdisciplinary consensus guidelines, the diff erent levels of evidence are translated into recommendations at diff erent strengths [ 5 , 7 , 17 ] . As these guidelines refl ect the current standard of care, they serve as an important orientation in the clinical management of patients. Furthermore, they facilitate harmonization of treatment, in particular in an interdisciplinary or international setting [ 10 , 11 ] . Diff erent types of studies can be distinguished, among others interventional clinical trials, diagnostic, prognostic, and quality of life studies. In all, hypotheses are tested that have been developed prospectively prior to patient recruitment. Clinical, epidemiology or pathology registries complement the arsenal of clinical studies and may guarantee complete recruitment, valid diagnosis and thus comparability [ 8 ] . Their most imminent contribution may be that they could allow recruitment of patients with very rare diseases, in which the knowledge about optimal diagnostic assessment and therapy may be limited, or where insuffi cient information is available to generate scientifi c hypotheses based on known estimates of case numbers necessary to answer these questions. Furthermore, epidemiology and pathology registries may be indispensible for a complete epidemiological survey of childhood cancers and for maintaining a high standard in histopathologic diagnosis and classifi cation. According to a strict exegesis, registries are not considered a clinical trial, because these registries do not obligatorily require a prospective defi nition of precise study questions. Nevertheless, they may fulfi ll some aspects of clinical studies such as diagnostic studies. In this comment, the diff erent aspects, strengths and weaknesses of clinical studies and registries established in pediatric oncology will be critically evaluated. Clinical interventional trials explore the clinical effi cacy and safety of a certain treatment, device or medical strategy. These include pharmacological and early clinical studies (phases 0, I), in which fi rst the feasibility of treatment is evaluated. 
by law. They must not be an easy escape from sound scientifi c evaluation or legislative burden with respect to issues of patient safety. Therefore, whenever possible, especially during interim phases between two interventional trails registries should be used for investigation of diagnostic questions. In very rare diseases, in which knowledge is very limited, however, registries may be the only way to generate any knowledge on the diseases. Without central registries, evidence about these orphan diseases would never reach beyond single case reports or small retrospective series. In these instances, registries may not necessarily require adherence to a uniform therapeutic recommendation. Since the study parameters integrated in the database must be defi ned, the potential heterogeneity in treatment has to be considered in advance [ 4 ] . However, in order to maintain a high standard of care and to reduce heterogeneity in clinical management, a recommendation refl ecting the current standard should be provided [ 24 ] . As the competence for this disease will also be highest at the coordination centers, they should also off er consultation in diffi cult cases [ 4 , 23 ] . In this context, the integration of reference pathology (and genetic) evaluation may be essential, in particular in rare and heterogeneous diseases, as this may allow a uniform classifi cation which could lead to the introduction of a diagnostic standard in these often heterogeneous diseases [ 6 ] . This approach has been taken in some disease-specifi c registries, e. g. for sex cord stromal tumors, pleuropulmonary blastoma or NUT midline carcinomas [ 9 , 14 , 24 ] . However, these disease specifi c registries mainly fulfi ll the criteria for diagnostic studies rather than being pure registries. Last but not least, the registries should also be submitted to ethical evaluation and approval. In conclusion, there is a hierarchy of the scientifi c impact of registries, diagnostic and clinical interventional studies. Registries certainly constitute an important motor of scientifi c progress in very rare diseases, as they allow a complete documentation of even highly heterogeneous disorders and may provide a comprehensive survey of the studied disease. However, on the basis of complete registration, study questions should be defi ned so that diagnostic and ideally, clinical interventional studies can be developed. The latter should still be the standard of management in the major childhood cancers.
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The authors have no confl ict of interest to disclose. specifi c diagnostic test compared to patients who have not been tested [ 22 ] . Of note, diagnostic studies do not include a comparison of diff erent therapeutic strategies. Instead, patients can be treated according to current standards. Nevertheless, documentation of treatment, toxicity and outcome is often required to answer the diagnostic questions. Thus, diagnostic studies may provide a similar overview on the clinical course to interventional trials, without the administrative workload of clinical interventional trials according to drug legislation. Moreover, the improvement of diagnostic accuracy and risk stratifi cation may allow for a substantial improvement of the clinical management of these patients. In addition, these diagnostic studies may also reveal biological phenomena that may have a signifi cant impact on the understanding of a specifi c disease [ 13 ] . The EWOG-MDS studies are a successful example for such a study concept [ 21 , 25 ] As a third approach to the generation of evidence, registries have to be appraised. In pediatric oncology, diff erent types of registries have successfully been established, and much of our current knowledge has been derived from these data. In Germany, the epidemiological German Childhood Cancer Registry and the pathology Childhood Tumor Registry or Brain Tumor Registry provide a comprehensive survey of the spectrum of childhood cancers. These registries have also been the basis for the implementation of numerous diagnostic studies that focus on pathology or genetic aspects [ 15 , 16 ] . Thus, the registries have revealed signifi cant information regarding epidemiological risk factors, tumor classifi cation, risk stratifi cation and prognosis. By the inclusion of long-term follow-up queries, these registries are also helpful in the research on long-term sequelae after childhood cancer treatment [ 12 ] . The development of clinical registries has seen a signifi cant change during the last decade. The impulse for this change came from the new legislative regulations for clinical studies [ 20 ] . About 20 years ago, most pediatric cancers were treated within prospective multicenter therapy optimization trials. However, a considerable number of studies have now been transformed into clinical registries. In some instances, prospective trials have ended recruitment, but the next trial generation has not yet been initiated. Here, clinical registries have been established to cover the interim phase and to provide quality controlled treatment by providing precise recommendations for diagnostics and treatment. For safety reasons clinical, pathology and follow-up data are documented prospectively and annual reports are provided. In contrast to phase IV trails, these registries do not necessarily serve to evaluate a specifi c study hypothesis or study question. As the registries off er access to central diagnostic confi rmation and consultation, central data management and standardization of treatment, these registries are important for maintaining the high therapeutic standard in pediatric oncology patients not enrolled into interventional or diagnostic studies. For entities, for which no interventional or diagnostic study is currently possible, registries may also play an important role in allowing for a complete registration of all patients reported with this specifi c diagnosis. It should be considered that the complete registration of a specifi c diagnosis per se is not a scientifi c goal, if no scientifi c questions are evaluated in a sound approach. In fact, compared to clinical interventional or diagnostic trials, registries may be at a certain risk to suff er from several weaknesses in scientifi c methodology. Therefore, to allow the best possible scientifi c evaluation of patients, registries have to be designed as This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
